- Conditions
- Type2 Diabetes Mellitus, Atherosclerotic Cardiovascular Disease
- Interventions
- Initiation of tirzepatide, Initiation of sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 49,065 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 22, 2026, 1:13 AM EDT